Teva Pharmaceutical Industries Ltd (TEVA)

TEVA (NYSE:Drugs) EQUITY
$36.30
pos +0.00
+0.00%
Today's Range: 36.15 - 36.86 | TEVA Avg Daily Volume: 9,568,100
Last Update: 12/09/16 - 4:02 PM EST
Volume: 0
YTD Performance: -44.70%
Open: $0.00
Previous Close: $35.91
52 Week Range: $34.57 - $66.55
Oustanding Shares: 1,015,000,000
Market Cap: 36,448,650,000
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 8 10 10
Moderate Buy 1 2 2 2
Hold 7 7 5 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.94 1.91 1.68 1.59
Latest Dividend: 0.29
Latest Dividend Yield: 3.22%
Dividend Ex-Date: 12/01/16
Price Earnings Ratio: 7.12
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
7.12 20.80 31.10
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-27.70% -44.55% -9.59%
GROWTH 12 Mo 3 Yr CAGR
Revenue -3.10 0.00 -0.01
Net Income -47.50 -0.20 -0.06
EPS -48.90 -0.20 -0.06
Earnings for TEVA:
EBITDA 5.79B
Revenue 19.65B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $1.42 $n.a. $5.13 $5.60
Number of Analysts 2 0 2 2
High Estimate $1.43 $n.a. $5.14 $5.94
Low Estimate $1.41 $n.a. $5.11 $5.25
Prior Year $1.28 $1.18 $5.42 $5.13
Growth Rate (Year over Year) 10.94% n.a.% -5.44% 9.17%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Paul Price

 | Dec 8, 2016 | 8:00 AM EST
Here are stocks with solid fundamentals at some of the best absolute entry points in years.
By

Bruce Kamich

 | Dec 6, 2016 | 11:04 AM EST
Wait for a bounce and then a retest before stepping up to buy.
RMPIA
By

Bret Jensen

 | Nov 28, 2016 | 11:00 AM EST
Small-caps could also benefit from abating tax-loss selling.
RMPIA
By

Real Money

 | Nov 25, 2016 | 2:00 PM EST
'Milestone payments' could boost deal's $125 million announced price.
By

Bret Jensen

 | Nov 16, 2016 | 10:09 AM EST
And we are off.
RMPIA
By

Bret Jensen

 | Nov 16, 2016 | 7:33 AM EST
It is good to be standing in for Doug Kass this Wednesday.

bearishTeva downgraded at Jefferies

Nov 16, 2016 | 7:22 AM EST
TEVA was downgraded from Buy to Hold, Jefferies said. $40 price target. Company is facing multiple growth headwinds.
RMPIA
By

Jim Cramer

 | Nov 15, 2016 | 11:29 AM EST
In these market crosscurrents, it's tough to go with the flow.
RMPIA
By

Bret Jensen

 | Nov 4, 2016 | 10:07 AM EDT
Thursday felt a lot like capitulation in this space. I was buying.
RMPIA
By

Doug Kass

 | Nov 3, 2016 | 3:44 PM EDT
The U.S. dollar strengthened. The price of crude oil continued to roll over: down $0.66 to $44.68. Ag commodities: wheat down $0.05, corn up $0.02, soybeans up $0.03 and oats down $0.04. Lumber up $5. Bonds got schmeissed (iShares Barclays 20+ Yr Treas.Bond ETF (TLT) down a beaner) after staging a two-day recovery. The 10-year U.S. Treasury rose by 2 basis points in yield while the long bond advanced by 4 basis points. The 2s/10s spread rose back to 100 bps. Municipals were flat to higher. Junk bond prices edged a bit higher as well. Blackstone/GSO Strategic Credit Fund (BGB)  up $0.02. Banks were mixed. Our Trade of the Week made a morning move higher -- and then dropped to new daily lows. I added on the short side. Financial Select Sector SPDR Fund (XLF) up by $0.08. Insurance was very strong after a Lincoln National (LNC) beat (I remain small short). Hartford Financial (HIG) lacked this time. Brokerages are surprisingly strong, led by Goldman Sachs (GS) . Old tech down - with Comcast (CSCO) , Microsoft (MSFT) and Intel (INTC) lower. Retail still stinking up the joint with Nordstrom (JWN) , Target (TGT) , Foot Locker (FL) et al. notably weaker. I added to a poorly performing JC Penney (JCP) today. Awful sentiment in biotech, pharma and generic -- for obvious reasons. Biotech was a biowreck, breaking support levels. Allergan (AGN)  , Valeant Pharmaceuticals (VRX)  , Merck (MCK) etc lower. Speculative biotech like Sage Therapeutics (SAGE)  , Portula Pharmaceuticals (PTLA) ,  Acadia Pharmaceuticals (ACAD) , Aerie Pharmaceut
From The Restaurant Finance Monitor...


...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.